Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership

Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets.

The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of the products, which will target key therapeutic areas including cardiovascular and metabolic disorders.

Cadila operates manufacturing facilities in the US, UK, European Union, and Australia, and its products are distributed in over 100 countries, supported by a workforce of more than 9,000 professionals and a research and development division comprising more than 350 scientists.

Expanding Commercial Footprint

Algorae chief commercial officer Vishal Shah said the agreement would expand Algorae’s commercial footprint into new regions.

“This deal represents an important step in executing our commercial strategy and expanding our product portfolio through a world-class manufacturing partner,” he said.

Algorae representatives recently met with senior management and technical teams at Cadila’s headquarters in Ahmedabad to secure the new agreement.

Cadila’s R&D department works across key therapeutic areas such as respiratory, cardiometabolic, gastrointestinal, oncology, anti-infective, and pain management.

“With a diversified portfolio, strong regulatory track record, and commitment to sustainable growth, Cadila remains a trusted partner in improving access to healthcare worldwide,” Mr Shah added.

Executive Appointment

Algorae has appointed pharmaceutical executive David Gulland as chief operating officer to lead its operational and commercial scale-up initiatives.

Mr Gulland has more than 20 years of experience spanning private healthcare funding and pharmacy services—most recently as general manager of HPS Pharmacies, a division of Australasian pharmaceutical wholesaler and distributor EBOS Group (ASX: EBO).

In this role, he led enterprise-wide initiatives in digital transformation, supply chain optimisation and organisational restructuring, and pioneered Australia’s first private healthcare in-home funding model.

Mr Gulland will commence work with Algorae in March 2026.